Genome-wide association study identifies four SNPs associated with response to platinum-based neoadjuvant chemotherapy for cervical cancer

• DOI: 10.1038/srep41103
• Publication Date: 2017-01-25T10:42:29Z
• Authors: Xiong Li; Kecheng Huang; Qinghua Zhang; Jin Zhou; Haiying Sun; Fangxu Tang; Hang Zhou; Ting Hu; Shaoshuai Wang; Yao Jia; Ru Yang; Yile Chen; Xiaodong Cheng; Weiguo Lv; Li Wu; Hui Xing; Lin Wang; Shasha Zhou; Yuan Yao; Xiaoli Wang; Quzhen Suolang; Jian Shen; Ling Xi; Junbo Hu; Hui Wang; Gang Chen; Qinglei Gao; Xing Xie; Shixuan Wang; Shuang Li; Ding Ma
• Keywords: Adult; Uterine Cervical Neoplasms; Antineoplastic Agents; Middle Aged; Polymorphism, Single Nucleotide; Survival Analysis; Article; 3. Good health; Young Adult; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Asian People; Drug Therapy; Humans; Female; Aged; Genome-Wide Association Study; Platinum

AbstractTo identify genomic markers associated with the response to neoadjuvant chemotherapy (NACT) in patients with cervical cancer, we performed a three-stage genome-wide association study (GWAS) in the Han Chinese population. A total of 596 patients with stage IA2-IIIB cervical cancer were enrolled in this study. One single nucleotide polymorphism (SNP) (rs6812281, per allele OR = 2.37, P = 9.0 × 10−9) located at 4q34.3 reached GWAS significance (P < 5.0 × 10−8). Another three SNPs, rs4590782 (10q26.2, P = 1.59 × 10−5, per allele OR = 0.48), rs1742101 (14q32.11, P = 7.11 × 10−6, per allele OR = 0.52), and rs1364121 (16q23.3, P = 3.15 × 10−6, per allele OR = 1.98), exhibited strong evidence of associations with response to neoadjuvant chemotherapy. Patients with a C allele (CT + CC) of rs4590782 had better 5-year overall survival rates (82.9% vs. 75.8%, P = 0.083) and 5-year disease-free survival rate (80.8% vs. 72.7%, P = 0.021) than those without a C allele. Our findings help to characterize the genetic etiology of the response to neoadjuvant chemotherapy in patients with cervical cancer.